"EXTENDED CONTENTS" [2019] ELECD 1261; in Figueroa, Pablo; Guerrero, Alejandro (eds), "EU Law of Competition and Trade in the Pharmaceutical Sector" (Edward Elgar Publishing, 2019) vii

Book Title: EU Law of Competition and Trade in the Pharmaceutical Sector

Editor(s): Figueroa, Pablo; Guerrero, Alejandro

Publisher: Edward Elgar Publishing

Section Title: EXTENDED CONTENTS

Number of pages: 8

Extract:

EXTENDED CONTENTS




List of figures xv
List of tables xvi
List of contributors xvii
Table of cases xix
Table of legislation xxxviii

1 Competition law and pharma: an economic perspective
Benoît Durand
1. INTRODUCTION 1.1
2. AN R&D INTENSIVE INDUSTRY 1.21
3. THE DETERMINANTS OF R&D INTENSITY IN THE PHARMACEUTICAL INDUSTRY 1.24
4. COMPETITION AND THE PATENT SYSTEM 1.28
5. DELAYING THE ENTRY OF GENERICS 1.35
A. Strategic use of the patent system 1.41
B. Product hopping 1.48
C. Disparaging the generic version 1.52
6. THE EFFECTS OF PARALLEL TRADE 1.55
A. The development of parallel imports in the EEA 1.60
B. The effect of parallel imports on prices 1.65
C. The effect of parallel imports on innovation 1.70
7. THE DEMAND AND PRICING OF PHARMACEUTICAL PRODUCTS 1.78
A. Demand for pharmaceuticals: institutional details 1.80
B. Countervailing buyer power in the pharmaceutical industry 1.84
C. In-hospital and out-of-hospital pricing 1.93

2 Reverse payments: an EU and US perspective
Frank Maier-Rigaud, Nathan Blalock and Oliver Gannon
1. INTRODUCTION 2.1
A. Overview of recent investigations by competition authorities 2.6
B. Existence of beneficial reverse payment settlements 2.10
C. Effects-based analysis of restrictions is required in the assessment of reverse
payment settlements 2.12
2. SETTLEMENT AS THE OUTCOME OF IMPERFECT INFORMATION 2.15
3. WHAT ARE REVERSE PAYMENT SETTLEMENTS? 2.19
4. THE INCENTIVES OF ...